Annual Report • Oct 25, 2017
Annual Report
Open in ViewerOpens in native device viewer
Nolato AB (publ) nine-month interim report 2017
| Q3 | Q3 | Q1 - Q3 | Q1 - Q3 | Rolling | Full year | |
|---|---|---|---|---|---|---|
| SEK million unless otherwise specified | 2017 | 2016 | 2017 | 2016 | 12 months | 2016 |
| Net sales | 1,749 | 1,036 | 4,794 | 3,095 | 6,146 | 4,447 |
| Operating profit (EBITDA) 1) | 263 | 149 | 694 | 456 | 874 | 636 |
| Operating profit (EBITA) 2) | 209 | 104 | 533 | 327 | 663 | 457 |
| EBITA margin, % | 11.9 | 10.0 | 11.1 | 10.6 | 10.8 | 10.3 |
| Operating profit (EBIT) 3) | 206 | 101 | 522 | 317 | 648 | 443 |
| Profit after financial income and expense | 198 | 101 | 506 | 313 | 631 | 438 |
| Profit after tax | 153 | 79 | 392 | 241 | 487 | 336 |
| Earnings per share, basic and diluted, SEK * | 5.82 | 3.00 | 14.90 | 9.16 | 18.51 | 12.77 |
| Adjusted earnings per share, basic and diluted, SEK 4) * | 5.93 | 3.12 | 15.24 | 9.47 | 18.96 | 13.19 |
| Cash flow after investments, excl. acquisitions and disp. | 308 | 19 | 339 | 110 | 474 | 245 |
| Net investm. affecting cash flow, excl. acq. and disp. | 73 | 51 | 212 | 166 | 267 | 221 |
| Cash conversion, % 5) | — | — | — | — | 73 | 55 |
| Return on capital employed, % | 24.7 | 22.4 | 24.7 | 22.4 | 24.7 | 20.6 |
| Return on shareholders' equity, % | 26.2 | 19.7 | 26.2 | 19.7 | 26.2 | 19.0 |
| Equity/assets ratio, % | 42 | 58 | 42 | 58 | 42 | 47 |
| Net financial liabilities (–) | – 324 | – 51 | – 324 | – 51 | – 324 | – 408 |
* At the end of the period the Group had a share warrant programme (Series 1). The programme is from 2016 with redemption from 1 May 2019 to 15 December 2019. The subscription price is SEK 296.30. The programme has been taken into account in calculating the number of shares after dilution. Upon full subscription, the programme provides a maximum of 240,500 new class B shares.
1) Operating profit (EBITDA): Earnings before financial income and expense, taxes and depreciation/amortisation.
2) Operating profit (EBITA): Earnings before financial income and expense, taxes and amortisation of intangible assets arising from acquisitions.
3) Operating profit (EBIT): Earnings before financial income and expense and taxes.
4) Adjusted earnings per share: Profit after tax, excluding amortisation of intangible assets arising from acquisitions, divided by the average number of shares.
5) Cash conversion: Cash flow after investments, excl. acquisitions and disposals, divided by operating profit (EBIT). Cash flow and operating profit have been adjusted by non-recurring items, if any.
This document is a translation from Swedish. In the event of any difference between this version and the Swedish original, the latter shall prevail.
Consolidated sales rose by 69% to SEK 1,749 million (1,036). Adjusted for currency and acquisitions, sales growth was a very strong 57%. Organic growth was strong for all business areas, but was exceptionally strong for Integrated Solutions.
Medical Solutions sales rose to SEK 459 million (395); adjusted for currency and acquisitions, sales increased by 6%. Sales increased in both Medical Devices and Pharma Packaging and most customer segments experienced positive growth.
Integrated Solutions sales rose to SEK 819 million (343); adjusted for currency, sales increased by an exceptionally strong 143%. Launch Vaporiser Heating Products (VHP) volumes, within the e-cigarette segment, remained very high in the quarter. These volumes have been sustained into the fourth quarter.
Industrial Solutions sales amounted to SEK 473 million (301); adjusted for currency and acquisitions, sales increased by a very strong 27%. There was positive development of volumes in almost all segments, particularly automotive and hygiene. Invoicing of development work and production equipment for forthcoming production contributed to the strong growth in the quarter.
The Group's operating profit (EBITA) doubled to SEK 209 million (104).
Operating profit (EBITA) increased to SEK 60 million (52) for Medical Solutions, to SEK 105 million (29) for Integrated Solutions and to SEK 47 million (30) for Industrial Solutions.
The EBITA margin for Medical Solutions was 13.1% (13.2). The EBITA margin for Integrated Solutions rose to a very strong 12.8% (8.5). Very high volumes and consequent high capacity utilisation had a positive effect on the margin. The EBITA margin for Industrial Solutions was 9.9% (10.0).
Overall, the Group's EBITA margin was a very strong 11.9% (10.0).
| Sales | Sales | Op. profit | Op. profit | EBITA margin | EBITA margin | |
|---|---|---|---|---|---|---|
| SEK million | Q3/2017 | Q3/2016 | EBITA Q3/2017 | EBITA Q3/2016 | Q3/2017 | Q3/2016 |
| Medical Solutions | 459 | 395 | 60 | 52 | 13.1% | 13.2% |
| Integrated Solutions | 819 | 343 | 105 | 29 | 12.8% | 8.5% |
| Industrial Solutions | 473 | 301 | 47 | 30 | 9.9% | 10.0% |
| Intra-Group adj., Parent Co | – 2 | – 3 | – 3 | – 7 | — | — |
| Group total | 1,749 | 1,036 | 209 | 104 | 11.9% | 10.0% |
Operating profit (EBITA): Earnings before financial income and expense, taxes and amortisation of intangible assets arising from acquisitions.
Operating profit (EBIT) more than doubled to SEK 206 million (101).
Profit after net financial income/expense was SEK 198 million (101). Net financial income/expense included currency exchange rate fluctuations affecting earnings by SEK –4 million (+1).
Profit after tax rose to SEK 153 million (79). Earnings per share, basic and diluted, stood at SEK 5.82 (3.00). Adjusted earnings per share excluding amortisation of intangible assets arising from acquisitions were SEK 5.93 (3.12).
Consolidated sales rose by 55% to SEK 4,794 million (3,095) in the first nine months of 2017. Adjusted for currency and acquisitions, sales rose by a strong 39%.
Sales for Medical Solutions rose by 22% to SEK 1,444 million (1,182), for Integrated Solutions by 100% to 1,910 million (954) and for Industrial Solutions by 50% to SEK 1,450 million (966).
Consolidated operating profit (EBITA) amounted to SEK 533 million (327) and the EBITA margin was 11.1% (10.6). Operating profit (EBIT) was SEK 522 million (317).
Profit after net financial income/expense rose to SEK 506 million (313). Profit after tax was SEK 392 million (241). Earnings per share, basic and diluted, were SEK 14.90 (9.16). Adjusted earnings per share excluding amortisation of intangible assets arising from acquisitions increased to SEK 15.24 (9.47). The effective tax rate was 22.5% (23.0).
The return on capital employed was 24.7% for the last twelve months (20.6% for the 2016 calendar year). Return on equity was 26.2% for the last 12 months (19.0% for the 2016 calendar year). Cash conversion for the last twelve months was 73% (55% for the 2016 calendar year).
| Sales and profit Q1-Q3 (SEK million) | 2017 | 2016 |
|---|---|---|
| Sales | 1,444 | 1,182 |
| Operating profit (EBITA) | 189 | 157 |
| EBITA margin (%) | 13.1 | 13.3 |
| Operating profit (EBIT) | 181 | 147 |
Medical Solutions sales rose to SEK 1,444 million (1,182); adjusted for currency and acquisitions, sales growth was a strong 9%. Volumes increased in both the Medical Devices and Pharma Packaging sectors, but especially in Medical Devices in which the ramp-up of new customer projects made a positive contribution.
Operating profit (EBITA) rose to SEK 189 million (157). The EBITA margin was 13.1% (13.3).
The businesses acquired last year are performing well and according to plan. Owing to the strong growth of recent years, Nolato will be expanding production capacity in Hungary, Sweden and Switzerland.
| Sales and profit Q1-Q3 (SEK million) | 2017 | 2016 |
|---|---|---|
| Sales | 1,910 | 954 |
| Operating profit (EBITA) | 216 | 90 |
| EBITA margin (%) | 11.3 | 9.4 |
| Operating profit (EBIT) | 216 | 90 |
Integrated Solutions sales rose sharply to SEK 1,910 million (954); adjusted for currency, sales growth was an exceptionally strong 97%. Last year, volumes were low for the first six months. The focus on expanding this business area's customer and product base showed highly positive development in the second and third quarters, particularly for VHP, within the e-cigarette segment. In addition, mobile phone projects produced good volumes.
Operating profit (EBITA) increased very sharply to SEK 216 million (90). The EBITA margin was a strong 11.3% (9.4). High volumes and consequent high capacity utilisation had an effect on the margin.
| Sales and profit Q1-Q3 (SEK million) | 2017 | 2016 |
|---|---|---|
| Sales | 1,450 | 966 |
| Operating profit (EBITA) | 143 | 98 |
| EBITA margin (%) | 9.9 | 10.1 |
| Operating profit (EBIT) | 140 | 98 |
Industrial Solutions sales increased to SEK 1,450 million (966); adjusted for currency and acquisitions, sales growth was a strong 20%. There was positive development of volumes in most segments, particularly automotive and hygiene. Advanced market positions and a high level of invoicing for development work and production equipment for forthcoming production contributed to the strong growth.
Operating profit (EBITA) increased to SEK 143 million (98), with an EBITA margin of 9.9% (10.1). The acquisition made last year is performing well and according to plan.
Significantly higher earnings have resulted in strong cash flow after investments. On an accumulated basis for the nine-month period, it amounted to SEK 339 million (SEK 110 million excluding acquisitions, SEK 94 million including acquisitions). The change in working capital was a negative SEK 38 million (–91). Net investments affecting cash flow increased to SEK 212 million (SEK 166 million excluding acquisitions). Including acquisitions last year, net investments amounted to SEK 212 million (182).
Cash flow after investments for the third quarter increased to SEK 308 million (SEK 19 million excluding acquisitions). The sharp increase in earnings contributed to this, and there was a significant positive change in working capital in the quarter. The strong need for working capital during the second quarter's considerable increase in sales was reduced in the third quarter through increased trade payables and reduced trade receivables. Trade receivables were reduced despite increasing sales through the use of supplier finance among the Group's customers and sales of more trade receivables than before.
Nolato's financial position remains solid, but debt has increased as a result of higher activity and growth. Interest-bearing assets totalled SEK 561 million (240), and interest-bearing liabilities and provisions totalled SEK 885 million (291).
In the second quarter, dividends totalling SEK 276 million (263) were paid out. Consequently, net debt amounted to SEK 324 million (51). Shareholders' equity was SEK 1,950 million (1,741). The equity/assets ratio was 42% (58).
One of the Group's credit agreements was extended and increased in the second quarter. Consequently, Nolato has long-term credit agreements between four and five years totalling approximately SEK 1.1 billion. It also has short-term bank overdraft and similar facilities of approximately SEK 100 million.
| SEK million | 30/09/2017 | 30/09/2016 | 31/12/2016 |
|---|---|---|---|
| Interest-bearing liabilities, credit institutions | – 703 | – 160 | – 617 |
| Interest-bearing pension liabilities | – 182 | – 131 | – 202 |
| Total borrowings | – 885 | – 291 | – 819 |
| Cash and bank | 561 | 240 | 411 |
| Net financial liabilities (–) | – 324 | – 51 | – 408 |
| Working capital | 391 | 308 | 327 |
| As a percentage of sales (avg.) (%) | 5.7 | 5.9 | 5.9 |
| Capital employed | 2,836 | 2,033 | 2,668 |
| Return on capital employed (avg.) (%) | 24.7 | 22.4 | 20.6 |
| Shareholders' equity | 1,950 | 1,741 | 1,850 |
| Return on shareholders' equity (avg.) (%) | 26.2 | 19.7 | 19.0 |
The average number of employees during the period was 7,283 people (6,062). The increase in the number of employees is mainly attributable to Integrated Solutions' operations in China and personnel from acquired businesses.
The business risks and risk management of the Group and the Parent Company, along with the management of financial risks, are described in the 2016 Annual Report on pages 21, 56 – 57, and in Note 4 on pages 67 – 68.
No significant events have occurred during the period that would significantly affect or change these descriptions of the Group's and the Parent Company's risks or the management thereof.
Nolato does not experience any significant seasonal variations. However, in the third quarter sales within Industrial Solutions, and to a certain degree Medical Solutions, can be negatively affected by the fact that the holiday period falls in this quarter both for Nolato and its customers.
No significant events have occurred since the end of the period.
Nolato AB (publ), Swedish corporate identity number 556080-4592, is the Parent Company of the Nolato Group.
Nolato's Class B shares are listed on the Nasdaq Stockholm exchange in the Mid Cap segment, where they are included in the Industrials sector.
There were 13,177 shareholders at 30 September. The largest shareholders are the Jorlén family with 10%, the Boström family, the Hamrin family and Didner & Gerge Funds with 9% each, Lannebo Funds with 8% and SEB Investment Management with 3% of the capital.
This information is information that Nolato AB is obliged to publish pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the above contact persons, at 2:30 p.m. CET on 25 October 2017.
This report has not been audited by the Company's auditors.
For the Parent Company, which has no operational activities, sales amounted to SEK 40 million (40). Profit after financial income and expense amounted to SEK 76 million (67). Contingent liabilities amounted to 110 MSEK (129).
Nolato's consolidated accounts have been prepared in accordance with International Financial Reporting Standards (IFRS), as adopted by the EU.
The consolidated year-end report has been prepared in accordance with IAS 34 (Interim Financial Reporting) and the applicable provisions of the Swedish Annual Accounts Act. The Swedish Securities Market Act has been applied in relation to publication of this interim report.
The consolidated accounts have been prepared in accordance with the same principles as those applied in the most recent Annual Report, which are described in the 2016 Annual Report on pages 64 – 66.
The new or revised IFRS standards or IFRIC interpretations, which came into effect on 1 January 2017, have not had any material effect on the consolidated income statement or balance sheet.
The interim report for the Parent Company was prepared in accordance with Chapter 9 of the Swedish Annual Accounts Act.
IFRS 9 will be applied from 1 January 2018 but it is assessed that it will not have any material quantitative effect on the Group's accounting of financial instruments.
In qualitative terms, the new standard will affect Nolato's accounting and valuation policies in the next annual accounts with regard to financial instruments. Disclosures about the application of hedge accounting will also be updated.
In 2016, Nolato carried out a detailed analysis of major customer contracts within the Group's three business areas; Medical Solutions, Integrated Solutions and Industrial Solutions. Nolato's analysis reviewed the performance obligations included in such contracts and how they are fulfilled. Nolato has valued and established transaction prices, including an allocation for performance obligations.
This analysis has not been assessed to result in any need to amend current policies for the accounting of revenue from contracts with customers.
In qualitative terms, the standard will affect Nolato's accounting and valuation policies in the next annual accounts with regard to revenue recognition.
In accordance with a decision at Nolato's AGM on 26 April 2017, the five largest shareholders in terms of the number of votes at the end of September 2017 have appointed the following individuals to be included in Nolato's Nomination Committee ahead of the 2018 AGM: Henrik Jorlén (chairman), Gun Boström, Lovisa Hamrin, Carl Gustafsson (Didner & Gerge Funds) and Johan Ståhl (Lannebo Funds).
Shareholders who would like to submit proposals to the Nomination Committee can contact the chairman of the Nomination Committee, Henrik Jorlén, by email at [email protected] or by post at Kommendörsgatan 4, 269 77 Torekov, Sweden.
The Annual General Meeting will be held on 24 April 2018.
Torekov, 25 October 2017 Nolato AB (publ) Christer Wahlquist, President and CEO
Nolato develops and manufactures products in polymer materials such as plastic, silicone and TPE for customers within medical technology,
pharmaceuticals, telecom, automotive and other selected industrial sectors. Operations encompass everything from individual components, which the customer assembles in its own product, to complete products that are ready for delivery to a customer's client.
Nolato also develops and manufactures its own products, such as pharmaceutical packaging.
Nolato's business model is based on close, long-term, innovative collaboration with our customers. By being part of their process at an early stage and providing support during both the development and production phases, Nolato helps its customers create a product that is as competitive as possible.
Nolato creates added value for its customers and owners through progressive, leading technology, extensive expertise in development and design, advanced project management and highly efficient production.
| Q3 | Q3 | Q1 - Q3 | Q1 - Q3 | Rolling | Full year |
|---|---|---|---|---|---|
| 2017 | 2016 | 2017 | 2016 | 12 months | 2016 |
| 1,749 | 1,036 | 4,794 | 3,095 | 6,146 | 4,447 |
| – 1,467 | – 869 | – 4,026 | – 2,573 | – 5,186 | – 3,733 |
| 282 | 167 | 768 | 522 | 960 | 714 |
| 3 | — | 8 | 4 | 22 | 18 |
| – 26 | – 27 | – 87 | – 82 | – 120 | – 115 |
| – 48 | – 39 | – 152 | – 127 | – 195 | – 170 |
| – 5 | — | – 15 | — | – 19 | – 4 |
| – 76 | – 66 | – 246 | – 205 | – 312 | – 271 |
| 206 | 101 | 522 | 317 | 648 | 443 |
| – 8 | — | – 16 | – 4 | – 17 | – 5 |
| 198 | 101 | 506 | 313 | 631 | 438 |
| – 45 | – 22 | – 114 | – 72 | – 144 | – 102 |
| 153 | 79 | 392 | 241 | 487 | 336 |
| 57 | 48 | 172 | 139 | 226 | 193 |
| 5.82 | 3.00 | 14.90 | 9.16 | 18.51 | 12.77 |
| 5.82 | 3.00 | 14.90 | 9.16 | 18.51 | 12.77 |
| 26,307,408 | 26,307,408 | 26,307,408 | 26,307,408 | ||
| 26,307,408 | 26,307,408 | ||||
| 26,313,754 | 26,307,408 | 26,313,754 | 26,307,408 | 26,313,754 | 26,307,408 |
| 26,307,408 26,310,877 |
26,307,408 26,307,408 |
26,307,408 26,309,142 |
26,307,408 26,307,408 |
26,307,408 26,309,142 |
26,307,408 26,307,408 |
* At the end of the period the Group had a share warrant programme (Series 1). The programme is from 2016 with redemption from 1 May 2019 to 15 December 2019. The subscription price is SEK 296.30. The programme has been taken into account in calculating the number of shares after dilution. Upon full subscription, the programme provides a maximum of 240,500 new class B shares.
| Q3 | Q3 | Q1 - Q3 | Q1 - Q3 | Rolling | Full year |
|---|---|---|---|---|---|
| 2017 | 2016 | 2017 | 2016 | 12 months | 2016 |
| 153 | 79 | 392 | 241 | 487 | 336 |
| 1 | — | 17 | – 2 | 27 | 8 |
| — | — | – 3 | — | – 5 | – 2 |
| 1 | — | 14 | – 2 | 22 | 6 |
| – 19 | 9 | – 33 | 7 | – 28 | 12 |
| — | — | 4 | – 1 | 3 | – 2 |
| — | — | – 1 | — | – 1 | — |
| – 19 | 9 | – 30 | 6 | – 26 | 10 |
| – 18 | 9 | – 16 | 4 | – 4 | 16 |
| 135 | 88 | 376 | 245 | 483 | 352 |
* Financial instruments are measured at fair value in the statement of financial position, pursuant to measurement hierarchy Level 2.
| SEK million | 30/09/2017 | 30/09/2016 | 31/12/2016 |
|---|---|---|---|
| Assets | |||
| Non-current assets | |||
| Intangible non-current assets | 810 | 534 | 849 |
| Property, plant and equipment | 1,205 | 993 | 1,205 |
| Non-current financial assets | 2 | 2 | 2 |
| Other non-current receivables | 1 | 1 | 1 |
| Deferred tax assets | 42 | 44 | 46 |
| Total fixed assets | 2,060 | 1,574 | 2,103 |
| Current assets | |||
| Inventories | 534 | 302 | 393 |
| Accounts receivable | 1,109 | 717 | 819 |
| Other current assets * 2) | 348 | 192 | 198 |
| Cash and bank | 561 | 240 | 411 |
| Total current assets | 2,552 | 1,451 | 1,821 |
| Total assets | 4,612 | 3,025 | 3,924 |
| Shareholders' equity and liabilities | |||
| Shareholders' equity | 1,950 | 1,741 | 1,850 |
| Long-term liabilities and provisions 1) | 750 | 162 | 803 |
| Deferred tax liabilities 1) | 93 | 59 | 88 |
| Current liabilities and provisions * 1) 3) | 1,819 | 1,063 | 1,183 |
| Total liabilities and provisions | 2,662 | 1,284 | 2,074 |
| Total shareholders' equity and liabilities | 4,612 | 3,025 | 3,924 |
| 1) Interest-bearing/non-interest-bearing liabilities and provisions: | |||
| Interest-bearing liabilities and provisions | 885 | 291 | 819 |
| Non-interest-bearing liabilities and provisions | 1,777 | 993 | 1,255 |
| Total liabilities and provisions | 2,662 | 1,284 | 2,074 |
| * Financial instruments are measured at fair value in the statement of financial position, pursuant to | |||
| measurement hierarchy Level 2. | |||
| 2) Derivative assets are included in other current assets at | 31 | 12 | 10 |
| 3) Derivative liabilities are included in current liabilities and provisions at | — | 9 | 4 |
| 2016 2016 |
|---|
| 1,759 |
| 245 352 |
| – 263 – 263 |
| — 2 |
| 1,850 |
| 1,759 1,741 |
In 2017, a dividend totalling SEK 276 million was paid to the Parent Company's shareholders, corresponding to a dividend of SEK 10.50 per share. At the end of the period the Group had a share warrant programme (Series 1). The programme is from 2016 with redemption from 1 May 2019 to15 December 2019. The subscription price is SEK 296.30. The programme has been taken into account in calculating the number of shares after dilution. Upon full subscription, the programme provides a maximum of 240,500 new class B shares.
| Q3 | Q3 | Q1 - Q3 | Q1 - Q3 | Rolling | Full year | |
|---|---|---|---|---|---|---|
| SEK million | 2017 | 2016 | 2017 | 2016 | 12 months | 2016 |
| Cash flow from op. activities bef. changes in work. cap. | 225 | 122 | 589 | 367 | 729 | 507 |
| Changes in working capital | 156 | – 52 | – 38 | – 91 | 12 | – 41 |
| Cash flow from operating activities | 381 | 70 | 551 | 276 | 741 | 466 |
| Cash flow from investment activities | – 73 | – 67 | – 212 | – 182 | – 649 | – 619 |
| Cash flow before financing activities | 308 | 3 | 339 | 94 | 92 | – 153 |
| Cash flow from financing activities | – 102 | – 15 | – 154 | – 257 | 260 | 157 |
| Cash flow for the period | 206 | – 12 | 185 | – 163 | 352 | 4 |
| Cash and cash equivalents at the beginning of the period | 380 | 250 | 411 | 403 | — | 403 |
| Exchange rate difference in liquid assets | – 25 | 2 | – 35 | — | — | 4 |
| Cash and cash equivalents at the end of the period | 561 | 240 | 561 | 240 | — | 411 |
| Q3 | Q3 | Q1 - Q3 | Q1 - Q3 | Rolling | Full year | |
|---|---|---|---|---|---|---|
| SEK million | 2017 | 2016 | 2017 | 2016 | 12 months | 2016 |
| Profit after tax | 153 | 79 | 392 | 241 | 487 | 336 |
| Adjusted earnings: | ||||||
| Amortisation of intangible assets arising from acquis. | 3 | 3 | 11 | 10 | 15 | 14 |
| Tax on amortisation | — | — | – 2 | – 2 | – 3 | – 3 |
| Adjusted earnings | 156 | 82 | 401 | 249 | 499 | 347 |
| Average number of shares, before dilution * | 26,307,408 | 26,307,408 | 26,307,408 | 26,307,408 | 26,307,408 | 26,307,408 |
| Average number of shares, after dilution * | 26,310,877 | 26,307,408 | 26,309,142 | 26,307,408 | 26,309,142 | 26,307,408 |
| Earnings per share, before dilution (SEK) * | 5.82 | 3.00 | 14.90 | 9.16 | 18.51 | 12.77 |
| Earnings per share, after dilution (SEK) * | 5.82 | 3.00 | 14.90 | 9.16 | 18.51 | 12.77 |
| Adjusted earnings per share, before dilution (SEK) * | 5.93 | 3.12 | 15.24 | 9.47 | 18.96 | 13.19 |
| Adjusted earnings per share, after dilution (SEK) * | 5.93 | 3.12 | 15.24 | 9.47 | 18.96 | 13.19 |
| 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|
| Net sales (SEK million) | 4,447 | 4,726 | 4,234 | 4,522 | 3,874 |
| Operating profit (EBITA) (SEK million) | 457 | 570 | 470 | 427 | 303 |
| EBITA margin (%) | 10.3 | 12.1 | 11.1 | 9.4 | 7.8 |
| Operating profit (EBIT) (SEK million) | 443 | 556 | 454 | 411 | 287 |
| Profit after financial income and expense (SEK million) | 438 | 555 | 462 | 403 | 272 |
| Profit after tax (SEK million) | 336 | 420 | 364 | 314 | 202 |
| Cash flow after investments, excl. acq. and disposals (SEK million) | 245 | 288 | 127 | 362 | 317 |
| Cash conversion (%) | 55 | 52 | 28 | 82 | 111 |
| Return on capital employed (%) | 20.6 | 29.6 | 28.4 | 26.7 | 19.4 |
| Return on shareholders' equity (%) | 19.0 | 25.3 | 25.0 | 24.9 | 17.7 |
| Net financial liabilities (–) assets (+) (SEK million) | – 408 | 122 | 59 | 122 | – 113 |
| Equity/assets ratio (%) | 47 | 54 | 54 | 52 | 44 |
| Earnings per share, before and after dilution (SEK) * | 12.77 | 15.97 | 13.84 | 11.94 | 7.68 |
| Adjusted earnings per share, before and after dilution (SEK) * | 13.19 | 16.35 | 14.29 | 12.39 | 8.13 |
| Dividend per share (SEK) | 10.50 | 10.00 | 8.50 | 8.00 | 6.00 |
| Average number of employees | 6,418 | 7,759 | 8,020 | 9,357 | 8,421 |
* At the end of the period the Group had a share warrant programme (Series 1). The programme is from 2016 with redemption from 1 May 2019 to 15 December 2019. The subscription price is SEK 296.30. The programme has been taken into account in calculating the number of shares after dilution. Upon full subscription, the programme provides a maximum of 240,500 new class B shares.
| 2017 1,370 1,675 1,749 — — Net sales (SEK million) 2016 1,022 1,037 1,036 1,352 4,447 2015 1,073 1,280 1,084 1,289 4,726 Operating profit (EBITDA) (SEK million) 2017 199 232 263 — — 2016 155 152 149 180 636 2015 164 208 185 180 737 2017 146 178 209 — — Operating profit (EBITA) (SEK million) 2016 113 110 104 130 457 2015 123 167 142 138 570 2017 10.7 10.6 11.9 — — EBITA margin (%) 2016 11.1 10.6 10.0 9.6 10.3 2015 11.5 13.0 13.1 10.7 12.1 2017 142 174 206 — — Operating profit (EBIT) (SEK million) 2016 110 106 101 126 443 2015 119 163 139 135 556 2017 138 170 198 — — Profit after financial income and expense (SEK million) 2016 109 103 101 125 438 2015 121 162 137 135 555 2017 108 131 153 — — Profit after tax (SEK million) 2016 83 79 79 95 336 2015 93 125 105 97 420 2017 67 103 381 — — Cash flow from operating activities (SEK million) 2016 93 113 70 190 466 2015 217 9 153 153 532 Cash flow from operations per share basic & diluted (SEK) 2017 2.55 3.92 14.48 — — 2016 3.54 4.30 2.66 7.22 17.71 2015 8.25 0.34 5.82 5.82 20.22 2017 3 28 308 — — Cash flow after investments, excl. acq. and disp. (SEK million) 2016 30 61 19 135 245 2015 104 – 52 120 116 288 2017 0.11 1.06 11.71 — — Cash fl. aft. inv., excl. acq. and disp. per sh. bas. and dil. (SEK) 2016 1.14 2.32 0.72 5.13 9.31 2015 3.95 – 1.98 4.56 4.41 10.95 2017 4.11 4.98 5.82 — — Earnings per share, basic & diluted (SEK) 2016 3.16 3.00 3.00 3.61 12.77 2015 3.54 4.75 3.99 3.69 15.97 2017 4.22 5.09 5.93 — — Adjusted earnings per share, basic & diluted (SEK) 2016 3.23 3.12 3.12 3.72 13.19 2015 3.65 4.86 4.07 3.77 16.35 2017 74 69 74 — — Shareholders' equity per share, basic & diluted (SEK) * 2016 70 63 66 70 70 2015 65 60 64 67 67 2017 14.0 14.8 16.1 — — Return on total capital (%) 2016 17.8 16.0 14.7 13.7 13.7 2015 17.6 19.5 19.8 18.3 18.3 Return on capital employed (%) 2017 20.8 22.3 24.7 — — 2016 27.2 24.8 22.4 20.6 20.6 2015 28.5 31.6 32.0 29.6 29.6 Return on operating capital (%) 2017 24.3 25.7 29.1 — — 2016 34.2 28.9 26.1 24.4 24.4 2015 34.7 36.4 37.3 35.3 35.3 2017 20.0 22.9 26.2 — — Return on shareholders' equity (%) 2016 23.2 22.5 19.7 19.0 19.0 2015 25.1 30.1 29.6 25.3 25.3 2017 267.00 316.50 393.00 — — Closing share price Nolato B (Nasdaq Stockholm) 2016 227.50 221.50 263.00 263.00 263.00 2015 208.50 189.50 210.00 257.50 257.50 |
Q1 | Q2 | Q3 | Q4 | Full year | |
|---|---|---|---|---|---|---|
* At the end of the period the Group had a share warrant programme (Series 1). The programme is from 2016 with redemption from 1 May 2019 to 15 December 2019. The subscription price is SEK 296.30. The programme has been taken into account in calculating the number of shares after dilution. Upon full subscription, the programme provides a maximum of 240,500 new class B shares.
| Net sales (SEK million) | Q1 | Q2 | Q3 | Q4 | Full year | ||
|---|---|---|---|---|---|---|---|
| Medical Solutions | 2017 | 487 | 498 | 459 | — | — | |
| 2016 | 390 | 397 | 395 | 463 | 1,645 | ||
| 2015 | 344 | 365 | 368 | 387 | 1,464 | ||
| Integrated Solutions | 2017 | 399 | 692 | 819 | — | — | |
| 2016 | 300 | 311 | 343 | 448 | 1,402 | ||
| 2015 | 418 | 584 | 434 | 581 | 2,017 | ||
| Industrial Solutions | 2017 | 488 | 489 | 473 | — | — | |
| 2016 | 334 | 331 | 301 | 443 | 1,409 | ||
| 2015 | 312 | 332 | 282 | 325 | 1,251 | ||
| Group adjustments, Parent Company | 2017 | – 4 | – 4 | – 2 | — | — | |
| 2016 | – 2 | – 2 | – 3 | – 2 | – 9 | ||
| 2015 | – 1 | – 1 | — | – 4 | – 6 | ||
| Group total | 2017 | 1,370 | 1,675 | 1,749 | — | — | |
| 2016 | 1,022 | 1,037 | 1,036 | 1,352 | 4,447 | ||
| 2015 | 1,073 | 1,280 | 1,084 | 1,289 | 4,726 | ||
| Operating profit (EBITA) (SEK million) | Q1 | Q2 | Q3 | Q4 | Full year | ||
| Medical Solutions | 2017 | 65 | 64 | 60 | — | — | |
| EBITA margin (%) | 13.3 | 12.9 | 13.1 | — | — | ||
| 2016 | 52 | 53 | 52 | 59 | 216 | ||
| EBITA margin (%) | 13.3 | 13.4 | 13.2 | 12.7 | 13.1 | ||
| 2015 | 46 | 47 | 51 | 47 | 191 | ||
| EBITA margin (%) | 13.4 | 12.9 | 13.9 | 12.1 | 13.0 | ||
| Integrated Solutions | 2017 | 38 | 73 | 105 | — | — | |
| EBITA margin (%) | 9.5 | 10.5 | 12.8 | — | — | ||
| 2016 | 33 | 28 | 29 | 41 | 131 | ||
| EBITA margin (%) | 11.0 | 9.0 | 8.5 | 9.2 | 9.3 | ||
| 2015 | 47 | 101 | 63 | 61 | 272 | ||
| EBITA margin (%) | 11.2 | 17.3 | 14.5 | 10.5 | 13.5 | ||
| Industrial Solutions | 2017 | 48 | 48 | 47 | — | — | |
| EBITA margin (%) | 9.8 | 9.8 | 9.9 | — | — | ||
| 2016 | 34 | 34 | 30 | 36 | 134 | ||
| EBITA margin (%) | 10.2 | 10.3 | 10.0 | 8.1 | 9.5 | ||
| 2015 | 34 | 34 | 30 | 34 | 132 | ||
| EBITA margin (%) | 10.9 | 10.2 | 10.6 | 10.5 | 10.6 | ||
| Group adjustments, Parent Company | 2017 | – 5 | – 7 | – 3 | — | — | |
| 2016 | – 6 | – 5 | – 7 | – 6 | – 24 | ||
| 2015 | – 4 | – 15 | – 2 | – 4 | – 25 | ||
| Group total | 2017 | 146 | 178 | 209 | — | — | |
| EBITA margin (%) | 10.7 | 10.6 | 11.9 | — | — | ||
| 2016 | 113 | 110 | 104 | 130 | 457 | ||
| EBITA margin (%) | 11.1 | 10.6 | 10.0 | 9.6 | 10.3 | ||
| 2015 | 123 | 167 | 142 | 138 | 570 | ||
| EBITA margin (%) | 11.5 | 13.0 | 13.1 | 10.7 | 12.1 | ||
| Depreciation/amortisation (SEK million) |
Q1 | Q2 | Q3 | Q4 | Full year | ||
| Medical Solutions | 2017 | 27 | 27 | 27 | — | — | |
| 2016 | 22 | 22 | 23 | 25 | 92 | ||
| 2015 | 20 | 22 | 22 | 22 | 86 | ||
| Integrated Solutions | 2017 | 9 | 8 | 8 | — | — | |
| 2016 | 9 | 9 | 9 | 9 | 36 | ||
| 2015 | 11 | 11 | 10 | 10 | 42 | ||
| Industrial Solutions | 2017 | 21 | 22 | 23 | — | — | |
| 2016 | 14 | 15 | 16 | 20 | 65 | ||
| 2015 | 14 | 12 | 14 | 13 | 53 | ||
| Group total | 2017 | 57 | 57 | 58 | — | — | |
| 2016 | 45 | 46 | 48 | 54 | 193 | ||
| 2015 | 45 | 45 | 46 | 45 | 181 |
| Q3 | Q3 | Q1 - Q3 | Q1 - Q3 | Rolling | Full year | |
|---|---|---|---|---|---|---|
| 2017 | 2016 | 2017 | 2016 | 12 months | 2016 | |
| Net sales (SEK million) | 1,749 | 1,036 | 4,794 | 3,095 | 6,146 | 4,447 |
| Sales growth (%) | 69 | – 4 | 55 | – 10 | 40 | – 6 |
| Percentage of sales outside Sweden (%) | 84 | 67 | 81 | 72 | 82 | 76 |
| Operating profit (EBITDA) (SEK million) | 263 | 149 | 694 | 456 | 874 | 636 |
| Operating profit (EBITA) (SEK million) | 209 | 104 | 533 | 327 | 663 | 457 |
| EBITA margin (%) | 11.9 | 10.0 | 11.1 | 10.6 | 10.8 | 10.3 |
| Profit after financial income and expense (SEK million) | 198 | 101 | 506 | 313 | 631 | 438 |
| Profit margin (%) | 11.3 | 9.7 | 10.6 | 10.1 | 10.3 | 9.8 |
| Profit after tax (SEK million) | 153 | 79 | 392 | 241 | 487 | 336 |
| Return on total capital (%) | 16.1 | 14.7 | 16.1 | 14.7 | 16.1 | 13.7 |
| Return on capital employed (%) | 24.7 | 22.4 | 24.7 | 22.4 | 24.7 | 20.6 |
| Return on operating capital (%) | 29.1 | 26.1 | 29.1 | 26.1 | 29.1 | 24.4 |
| Return on shareholders' equity (%) | 26.2 | 19.7 | 26.2 | 19.7 | 26.2 | 19.0 |
| Equity/assets ratio (%) | 42 | 58 | 42 | 58 | 42 | 47 |
| Debt/equity (%) | 45 | 17 | 45 | 17 | 45 | 44 |
| Interest coverage ratio (times) | 52 | 68 | 56 | 79 | 55 | 67 |
| Net investments affecting cash flow, excl. acq. and disposals | 73 | 51 | 212 | 166 | 267 | 221 |
| (SEK million) | ||||||
| Cash flow after inv., excl. acq. and disp. (SEK million) | 308 | 19 | 339 | 110 | 474 | 245 |
| Cash conversion (%) | — | — | — | — | 73 | 55 |
| Net financial liabilities (–) | – 324 | – 51 | – 324 | – 51 | – 324 | – 408 |
| Earnings per share, basic and diluted (SEK) * | 5.82 | 3.00 | 14.90 | 9.16 | 18.51 | 12.77 |
| Adjusted earnings per share, basic and diluted (SEK) * | 5.93 | 3.12 | 15.24 | 9.47 | 18.96 | 13.19 |
| Cash flow from operations per share, basic and diluted (SEK) * | 14.48 | 2.66 | 20.94 | 10.49 | 28.17 | 17.71 |
| Cash flow per share, excl. acq. and disp., basic and diluted (SEK) * | 11.71 | 0.72 | 12.89 | 4.18 | 18.02 | 9.31 |
| Shareholders' equity per share, basic and diluted (SEK) * | — | — | 74 | 66 | — | 70 |
| Average number of employees | — | — | 7,283 | 6,062 | — | 6,418 |
* At the end of the period the Group had a share warrant programme (Series 1). The programme is from 2016 with redemption from 1 May 2019 to 15 December 2019. The subscription price is SEK 296.30. The programme has been taken into account in calculating the number of shares after dilution. Upon full subscription, the programme provides a maximum of 240,500 new class B shares.
| Q1 - Q3 | Q1 - Q3 | Rolling | Full year | |
|---|---|---|---|---|
| SEK million | 2017 | 2016 | 12 months | 2016 |
| Operating profit (EBIT) | ||||
| Medical Solutions | 181 | 147 | 237 | 203 |
| Integrated Solutions | 216 | 90 | 257 | 131 |
| Industrial Solutions | 140 | 98 | 175 | 133 |
| Group adjustments, Parent Company | – 15 | – 18 | – 21 | – 24 |
| Consolidated operating profit (EBIT) | 522 | 317 | 648 | 443 |
| Financial income and expense (not distributed by business areas) | – 16 | – 4 | – 17 | – 5 |
| Consolidated profit before tax | 506 | 313 | 631 | 438 |
| Q3 | Q3 | Q1 - Q3 | Q1 - Q3 | Rolling | Full year | |
|---|---|---|---|---|---|---|
| SEK million | 2017 | 2016 | 2017 | 2016 | 12 months | 2016 |
| Net sales | 13 | 14 | 40 | 40 | 46 | 46 |
| Selling expenses | – 1 | – 1 | – 5 | – 3 | – 7 | – 5 |
| Administrative expenses | – 10 | – 11 | – 39 | – 34 | – 49 | – 44 |
| Other operating income | 2 | 1 | 4 | 2 | 4 | 2 |
| Other operating expenses | – 5 | – 6 | – 18 | – 19 | – 26 | – 27 |
| Operating profit | – 1 | – 3 | – 18 | – 14 | – 32 | – 28 |
| Profit from participations in Group companies | — | 5 | 77 | 68 | 101 | 92 |
| Financial income | 11 | 5 | 21 | 15 | 26 | 20 |
| Financial expenses | 10 | 2 | – 4 | – 2 | – 16 | – 14 |
| Profit after financial income and expense | 20 | 9 | 76 | 67 | 79 | 70 |
| Appropriations | — | — | — | — | 241 | 241 |
| Tax | — | — | — | 1 | – 50 | – 49 |
| Profit after tax | 20 | 9 | 76 | 68 | 270 | 262 |
| Depreciation/amortisation | — | — | 1 | — | 1 | — |
Subsidiary Jan-Sep 2016
| SEK million | 30/09/2017 | 30/09/2016 | 31/12/2016 | |||||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Intangible fixed assets | 4 | — | — | |||||
| Property, plant and equipment | 1 | 1 | 1 | |||||
| Financial assets | 1,634 | 1,163 | 1,653 | |||||
| Deferred tax assets | 14 | 14 | 13 | |||||
| Total fixed assets | 1,653 | 1,178 | 1,667 | |||||
| Other receivables | 309 | 255 | 498 | |||||
| Cash and bank | — | 37 | 75 | |||||
| Total current assets | 309 | 292 | 573 | |||||
| Total assets | 1,962 | 1,470 | 2,240 | |||||
| Shareholders' equity and liabilities | ||||||||
| Shareholders' equity | 917 | 924 | 1,118 | |||||
| Untaxed reserves | 163 | 129 | 163 | |||||
| Other provisions | 13 | 12 | 13 | |||||
| Long-term liabilities | 514 | 55 | 545 | |||||
| Current liabilities | 355 | 350 | 401 | |||||
| Total shareholders' equity and liabilities | 1,962 | 1,470 | 2,240 | |||||
| Transactions with related parties: | ||||||||
| SEK million | Period | Services | Services | Interest | Interest | Res. from shares | Rec. fr. rel. part. | Liab. to rel. part. |
| Related party | sold | bought | income | expenses | in Group comp. | on bal. sh. date | on bal. sh. date | |
| Subsidiary | Jan-Sep 2017 | 40 | – 4 | 15 | — | 77 | 646 | 253 |
None of the company's Board members or senior executives currently have, or have previously had, any direct or indirect involvement in any business transaction with the company which is, or was, of an unusual character in terms of its conditions. Nor has the Group issued any loans, pledged any guarantees or entered into any surety arrangements for any of the company's Board members or senior executives.
40 – 3 15 — 68 635
227
Earnings for the period that are attributable to the parent company's owners divided by the average number of outstanding shares.
Nolato presents certain financial measures in this report that are not defined according to IFRS. Nolato considers that these measures provide valuable supplementary information for investors and company management, as they enable an assessment of trends and the company's performance. Since not all companies calculate financial measures in the same way, these are not always comparable to measures used by other companies. These financial measures should not therefore be regarded as substitutes for measures defined according to IFRS.
Profit after financial income and expense, plus financial expenses as a percentage of average total capital in the balance sheet.
Profit after financial income and expense, plus financial expenses as a percentage of average capital employed. Capital employed consists of total capital less non-interest-bearing liabilities and provisions.
Operating profit as a percentage of average operating capital. Operating capital consists of total capital less non-interest-bearing liabilities and provisions, less interest-bearing assets.
EBITA margin
Operating profit (EBITA) as a percentage of net sales.
The average basic number of shares comprises the parent company's weighted intangible assets arising from acquisitions. average number of outstanding shares during the period. After dilution, a weighted average of the shares that may be issued under the ongoing share warrant programme is added, but only insofar as the average listed share price for the period exceeds the subscription price of the warrants.
Profit after tax, excluding amortisation of intangible assets arising from acquisitions, divided by the average number of shares.
Cash flow from operating activities, divided by the average number of shares.
Return on total capital Cash flow per share, excl. acq. and disposals
Earnings before financial income and expense and tax.
Cash conversion Cash flow before financing activities, divided by the average number of shares.
Cash flow after investments, excl. acquisitions and disposals, divided by operating profit (EBIT). Cash flow and operating profit have been adjusted by non-recurring items, if any.
Interest-bearing liabilities and provisions less interest-bearing assets.
Profit after financial income and expense, plus financial expenses, divided by financial expenses.
Profit after tax as a percentage of average shareholders' equity. Earnings before financial income and expense, taxes and depreciation/ amortisation.
Earnings before financial income and expense, taxes and amortisation of
Interest-bearing liabilities and provisions divided by shareholders' equity.
Shareholders' equity as a percentage of total capital in the balance sheet.
Profit after financial income and expense as a percentage of net sales.
Some of the items reported relate to future events and actual outcomes may differ materially. In addition to those factors explicitly commented on, other factors may also materially affect the actual outcome, such as economic conditions, exchange rates and interest rate levels, political risks, competition and pricing, product development, commercialisation and technical difficulties, supply problems and customer credit losses.
Nolato AB, SE-269 04 Torekov, Sweden • Tel. +46 431 442290 • Fax +46 431 442291 Corp. id. number 556080-4592 • E-mail [email protected] • Website www.nolato.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.